Two cases of Mycobacterium microti derived tuberculosis in HIV-negative immunocompetent patients. by Niemann, S. et al.
Vol. 6, No. 5, September–October 2000 Emerging Infectious Diseases 539
Dispatches
Mycobacterium microti, which causes tuber-
culosis (TB) mainly in small rodents such as
voles, has been considered nonpathogenic for
humans (1-3). Considering the DNA sequences of
the 16S rRNA gene and the 16S-to-23S internal
transcribed spacer region, M. microti proved to be
a member of the Mycobacterium tuberculosis
complex. Primary isolation and differentiation by
classical biochemical tests are complicated by the
very slow growth of this species (1,2). The new
molecular spoligotyping method has recently
permitted the simultaneous detection and typing
of M. microti (1). This technique has been applied
in two retrospective studies of M. microti
infections in the Netherlands and England,
enabling identification of cases in llamas, cats,
and ferrets, as well as in five humans, only one of
whom was described as immunocompetent (1,4).
A case in an HIV-positive patient has been
described in detail by Foudraine and co-workers
(5). We report two cases of M. microti infection
causing pulmonary TB in Germany, representing
the second and third reported cases in HIV-
seronegative immunocompetent patients.
Case 1
In January 1999, an HIV-seronegative 53-
year-old man was hospitalized with a solid lesion
in the upper lobe of the right lung, first identified
in 1989. Computer tomography (CT) of the chest
showed two dense infiltrates, 3x2 cm and 6x5 cm,
without cavitation. The patient reported nonpro-
ductive cough and weight loss of 3 kg in 2 years.
He was a cigarette smoker (approximately 1
pack/day for 30 years). Chronic abuse of alcohol
began in 1992, after the initial diagnosis. An
elevated erythrocyte sedimentation rate was the
only abnormal laboratory finding. A tuberculin
skin test (5 units of PPD) had a 7-mm induration.
Sputum and bronchoalveolar lavage fluid were
smear negative for acid-fast bacilli (AFB).
Tuberculous granuloma were found in bronchial
and peribronchial lung tissue obtained by
bronchoscopy; however, no AFB or signs of
malignancy were detected. Anti-TB therapy was
started with isoniazid, rifampin, and pyrazina-
mide. The patient’s clinical condition improved,
and by November 1999 the pulmonary infiltrate
had almost completely resolved. In interviews,
the patient said that he had no extended
exposure to household or farm animals. He lives
in his own apartment in a town (population
14,000) in central Germany. No tuberculin skin
test-positive contact persons have been identified.
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One mycobacterial culture was grown from
bronchoalveolar lavage fluid in liquid media (12B
vial, BACTEC460TB, Becton Dickinson Microbi-
ology Systems, Cockeysville, MD) after 5 weeks
of incubation. Limited growth was observed on
Stonebrink medium (small colonies visible after
>6 weeks of incubation), and no growth was
detected on Loewenstein-Jensen medium. The
isolate was identified as M. tuberculosis complex
by gene probes (ACCUProbe, GenProbe, San
Diego,CA) and as llama-type M. microti by the
characteristic spoligotype pattern (Figure 1) (1).
After reculturing, the strain showed normal
growth in BACTEC 460TB (Becton Dickinson),
allowing drug-susceptibility testing that indi-
cated susceptibility to isoniazid, rifampin,
pyrazinamide, ethambutol, and streptomycin.
Because of the limited growth on solid media,
classical biochemical tests could not be per-
formed. The bacteria showed normal cell
morphologic features in several Ziehl-Neelsen-
stained microscopic preparations from cultures.
Case 2
A severely ill 58-year-old man sought medical
attention in April 1999. The patient was in poor
general condition, with weight loss (> 8 kg in the
last year), night sweats, occasional fever, fatigue,
and productive cough. He had a history of smoking
(10 cigarettes/day for at least 20 years) and
diabetes mellitus (diagnosed in 1980). A chest X-
ray in December 1983 showed no abnormalities of
the heart and lung. The current illness had onset
in early 1998, after which the patient was examined
intensively by a number of physicians. Several X-
rays of the chest indicated pulmonary disease
with progression to bilateral lesions, predomi-
nantly in the right lung (Figure 2a); however,
diagnosis was inconclusive. In September 1998,
the general condition of the patient had so
deteriorated that he was unable to work.
Cytopathologic examination of a hemorrhagic
pleural effusion in October 1998 showed lympho-
cytic-granulocytic pleuritis. X-ray examination
(Figure 2b) and CT scan (data not shown) in April
1999 showed bilateral fibrosis of the lung
parenchyma with a partial honeycomb pattern.
Comparison with the X-ray in early 1998
documented a clear progression of the changes in
the right lung.
Laboratory values were normal except for a
slightly elevated leukocyte count. A tuberculin
skin test (Mendel-Mantoux) and tests for HIV-1
and HIV-2 were negative. Fiberoptic bronchos-
copy showed chronic atrophic bronchitis without
signs of malignancy. For the first time, a
bronchial secretion specimen was smear positive
for AFB, and severe pulmonary TB was diagnosed.
After treatment was begun with isoniazid,
ethambutol, rifampin, streptomycin, and pyrazi-
namide, the patient’s clinical condition improved,
he recovered his normal weight, and the
clinical symptoms resolved. Despite restrictive
alterations in ventilatory function that corre-
lated with radiologic and histomorphologic
findings, the patient’s condition improved and
he has returned to work. An X-ray in January
2000 showed a consistent picture of the
fibrosing lung disease.
One liquid culture (MGIT, Becton Dickinson)
from a gastric aspiration obtained in April 1999
was positive for Mycobacteria in mid-June after 9
weeks of incubation. M. tuberculosis complex-
specific gene probes (ACCUProbe) were positive.
By the spoligotyping method, the isolate was
unequivocally identified as vole-type M. microti
(Figure 1). In contrast to the llama-type isolate,
even after reculturing, the vole isolate showed
very slow growth in liquid media and no growth
on solid media, making drug-susceptibility
testing and biochemical characterization impos-
sible. In the Ziehl-Neelsen-stained microscopic
preparation of both the bronchial secretion and
several cultures, the bacterial cells showed
normal morphologic features. In subsequent
interviews, the patient said that he had not been
exposed to household or farm animals. He lives in
a village in a rural area in southern Germany. No
tuberculin skin test-positive contact persons
have been identified.
Conclusions
We describe the first two cases of
pulmonary TB due to M. microti of the llama
and vole types, respectively, in German
patients. M. microti caused severe pulmonary
TB with extensive histopathologic changes in
Figure 1. Spoligotype patterns of the isolates obtained
from patient 1 (lane 1) and patient 2 (lane 2) and
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Figure 2. X-rays obtained in February 1998 (a) and April 1999 (b), of the chest of a 58-year-old patient.542 Emerging Infectious Diseases Vol. 6, No. 5, September–October 2000
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the lung of an HIV-seronegative immunocompe-
tent patient. As in the case reported by van
Soolingen et al. (1), our data confirm the potential
of  M. microti to cause clinical illness in
immunocompetent patients.
In contrast to the case reported by Foudraine
and co-workers (5), both patients responded well
to treatment with isoniazid, rifampin, and
pyrazinamide or isoniazid, ethambutol, rifampin,
streptomycin, and pyrazinamide, which indicates
that regular anti-TB therapy may be appropriate
for patients with M. microti infection.
As reported previously (1), primary isolation
and biochemical characterization of M. microti
are complicated by the slow growth of the
bacteria. The resultant diagnostic delay, espe-
cially if atypical pulmonary lesions are present,
may lead to false diagnosis and inadequate
treatment. Thus, infection with M. microti
should be considered in the differential diagnosis
of patients with typical signs of TB but no
bacteriologic proof. In these cases, spoligotyping
is a fast, reliable technique for identification and
differentiation of M. microti and other members
of the M. tuberculosis complex (1,6,7).
The vole-type strain showed only limited
growth during primary isolation and reculturing,
impeding further characterization. In contrast,
our results indicate that the llama-type
M. microti may show normal growth in BACTEC
460TB. Moreover, we demonstrated that drug-
susceptibility testing of clinical isolates of this
subtype may be performed in liquid media.
Transmission from rodents to humans has
been discussed as a possible pathway for the
acquisition of M. microti infection (1). Although
patients were interviewed, no source of infection
could be identified.
Because of the difficulty with primary
isolation and differentiation, the prevalence and
clinical importance of M. microti may have been
underestimated. Further studies based on molecu-
lar methods are needed to characterize the
epidemiology of this emerging human pathogen.
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